There is no established direct dose equivalence between Mounjaro 5mg and oral Wegovy
These are fundamentally different medications with distinct mechanisms of action, formulations, and dosing paradigms that cannot be directly converted on a milligram-to-milligram basis.
Why Direct Conversion is Not Possible
Different Drug Classes and Mechanisms
- Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist given as a once-weekly subcutaneous injection 1
- Wegovy (semaglutide) is a GLP-1 receptor agonist. The oral formulation you're asking about is actually not FDA-approved for obesity 1
Critical Clarification on Wegovy Formulations
Oral semaglutide is NOT approved as "Wegovy" for obesity management. The evidence shows:
- Oral semaglutide is FDA-approved only for type 2 diabetes at 14 mg daily 1
- Phase III trials tested oral semaglutide at 25 mg and 50 mg daily for obesity (OASIS-1 trial), achieving 17.1% weight loss at 50 mg 1
- Wegovy specifically refers to subcutaneous semaglutide 2.4 mg weekly for obesity 1, 2
Comparative Efficacy Data
If Comparing Mounjaro 5mg to Injectable Wegovy 2.4mg:
Based on head-to-head and network meta-analysis data:
Weight Loss Outcomes:
- Mounjaro 5 mg weekly: approximately 7.6-7.8 kg weight loss 3
- Wegovy (subcutaneous) 2.4 mg weekly: approximately 5.7 kg weight loss 3
- Mounjaro 5 mg produces roughly 2 kg more weight loss than Wegovy 2.4 mg 4, 5, 6
HbA1c Reduction (in diabetes):
- Mounjaro 5 mg: -2.0% reduction 3
- Semaglutide 1 mg: -1.9% reduction 3
- Tirzepatide demonstrates superior glycemic control across all doses 4
Model-Based Dose Equivalence Estimates:
Recent sophisticated modeling suggests:
- Semaglutide 2.4 mg ≈ Tirzepatide 10 mg (99.4% probability of equivalence) 5
- Semaglutide 7.2 mg ≈ Tirzepatide 15 mg (94.8% probability of equivalence) 5
- No equivalent semaglutide dose for Tirzepatide 5 mg - it falls between standard semaglutide doses 5
Clinical Bottom Line
You cannot convert Mounjaro 5mg to an "oral Wegovy" dose because:
- Oral semaglutide for obesity doesn't exist as an FDA-approved product
- Even if comparing to injectable Wegovy, Mounjaro 5mg is MORE potent than Wegovy 2.4mg
- The drugs have different mechanisms (dual vs. single receptor agonism)
- Bioavailability differs dramatically between oral and subcutaneous formulations
If the Clinical Question is About Switching:
From Mounjaro 5mg to injectable Wegovy: This would represent a step DOWN in efficacy. Patients would likely experience less weight loss and potentially less glycemic benefit 4, 6, 7.
If oral semaglutide becomes available for obesity: Based on OASIS-1 data, you would need approximately 50 mg daily oral semaglutide to match the 17.1% weight loss seen with injectable formulations 1 - but this still wouldn't directly equate to Mounjaro 5mg's efficacy profile.
Common Pitfall to Avoid:
Do not attempt milligram-to-milligram conversions between these agents. Efficacy is determined by receptor engagement, pharmacokinetics, and mechanism of action - not simply dose magnitude. Always base switching decisions on clinical trial data for each specific formulation and indication 1, 4, 5.